Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus

Trends in Immunology

Volumn 32, Issue 3, 2011, Pages 131-137

  Guihot, Amélie ^a   Bourgarit, Anne ^a   Carcelain, Guislaine ^a   Autran, Brigitte ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD8 ANTIGEN; CELL ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; T LYMPHOCYTE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOPATHOGENIC EFFECT; DNA SEQUENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; INTESTINE LYMPHATIC TISSUE; MYCOBACTERIUM AVIUM; NATURAL KILLER CELL; NONHUMAN; REVIEW; T LYMPHOCYTE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HOMEOSTASIS; HUMANS; VACCINATION;

EID: 79952100497     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2010.12.002     Document Type: Review

References (78)

1. Dorr P., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005, 49:4721-5432.
2. Volberding P.A., Deeks S.G. Antiretroviral therapy and management of HIV infection. Lancet 2010, 376:49-62.
3. Guihot A., et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. Aids 2010, 24:614-617.
4. Autran B., et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
5. French M.A. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin. Infect. Dis. 2009, 48:101-107.
6. Cheynier R., et al. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 1994, 78:373-387.
7. Vieillard V., et al. NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:10981-10986.
8. Gougeon M.L., Montagnier L. Programmed cell death as a mechanism of CD4 and CD8 T cell deletion in AIDS. Molecular control and effect of highly active anti-retroviral therapy. Ann. N. Y. Acad. Sci. 1999, 887:199-212.
9. Appay V., Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J. Pathol. 2008, 214:231-241.
10. Thiele J., et al. AIDS-related bone marrow lesions--myelodysplastic features or predominant inflammatory-reactive changes (HIV-myelopathy)? A comparative morphometric study by immunohistochemistry with special emphasis on apoptosis and PCNA-labeling. Anal. Cell Pathol. 1996, 11:141-157.
11. Douek D.C., et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396:690-695.
12. Feinberg M.B., et al. HIV tropism and CD4+ T-cell depletion. Nat. Med. 2002, 8:537.
13. Renaud M., et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. Aids 1999, 13:669-676.
14. Pakker N.G., et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat. Med. 1998, 4:208-214.
15. Carcelain G., et al. T cell changes after combined nucleoside analogue therapy in HIV primary infection. Aids 1999, 13:1077-1081.
16. Gorochov G., et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat. Med. 1998, 4:215-221.
17. Napolitano L.A., et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat. Med. 2001, 7:73-79.
18. Hunt P.W., et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 2003, 187:1534-1543.
19. Hazenberg M.D., et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat. Med. 2000, 6:1036-1042.
20. Morris L., et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J. Exp. Med. 1998, 188:233-245.
21. Autran B., et al. Restoration of the immune system with anti-retroviral therapy. Immunol. Lett. 1999, 66:207-211.
22. Viard J.P., et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. Aids 2004, 18:45-49.
23. Kaufmann G.R., et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis. 2005, 41:361-372.
24. Moore R.D., Keruly J.C. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin. Infect. Dis. 2007, 44:441-446.
25. Le Moing V., et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med. 2007, 8:156-163.
26. Gras L., et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J. Acquir. Immune Defic. Syndr. 2007, 45:183-192.
27. Rehr M., et al. Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J. Virol. 2008, 82:3391-3404.
28. Miller V., et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann. Intern. Med. 1999, 130:570-577.
29. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin. Infect. Dis. 2010, 50:1387-1396. The Antiretroviral Therapy Cohort Collaboration.
30. Hellerstein M.K., et al. Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J. Clin. Invest. 2003, 112:956-966.
31. Emu B., et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J. Virol. 2005, 79:14169-14178.
32. Li T.S., et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
33. Yamamoto T., et al. Effect of lentivirus encoding HIV-1 Nef-U3 shRNA on the function of HIV-specific memory CD4(+) T cells in patients with chronic HIV-1 infection. Aids 2009, 23:2265-2275.
34. McNeil A.C., et al. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13878-13883.
35. Komanduri K.V., et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat. Med. 1998, 4:953-956.
36. Sacre K., et al. Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J. Exp. Med. 2005, 201:1999-2010.
37. Matthews G.V., et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000, 96:2730-2734.
38. Gerard L., et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J. Acquir. Immune Defic. Syndr. 2002, 30:478-484.
39. Havlir D.V., et al. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. J. Infect. Dis. 2000, 182:1658-1663.
40. Shafran S.D., et al. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann. Intern. Med. 2002, 137:734-737.
41. Furrer H., et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N. Engl. J. Med. 1999, 340:1301-1306.
42. Kroon F.P., et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. Aids 1998, 12:F217-F223.
43. Lange C.G., et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. Aids 2003, 17:2015-2023.
44. Puissant-Lubrano B., et al. Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients. Vaccine 2009, 27:3576-3583.
45. Kaufmann G.R., et al. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. Aids 2000, 14:959-969.
46. Dragsted U.B., et al. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J. Infect. Dis. 2004, 190:148-155.
47. Brenchley J.M., et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 2004, 200:749-759.
48. Lynch H.E., et al. Thymic involution and immune reconstitution. Trends Immunol. 2009, 30:366-373.
49. Ledergerber B., et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999, 353:863-868.
50. Katlama C., et al. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study-ANRS 082. Aids 2002, 16:2027-2034.
51. Levy Y., et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. Aids 2005, 19:279-286.
52. Abrams D., et al. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 2009, 361:1548-1559.
53. Miller J.D., et al. Differentiation of CD8 T cells in response to acute and chronic viral infections: implications for HIV vaccine development. Curr. Drug Targets Infect. Disord. 2005, 5:121-129.
54. Rosenberg E.S., et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523-526.
55. Al-Harthi L., et al. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. Aids 2000, 14:761-770.
56. Cavert W., et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997, 276:960-964.
57. Ogg G.S., et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 1999, 73:797-800.
58. Carcelain G., et al. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J. Virol. 2001, 75:234-241.
59. Autran B., Carcelain G. AIDS. Boosting immunity to HIV-can the virus help?. Science 2000, 290:946-949.
60. Autran B., et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). Aids 2008, 22:1313-1322.
61. Kinloch-de Loes S., et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J. Infect. Dis. 2005, 192:607-617.
62. Saez-Cirion A., et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:6776-6781.
63. Dhasmana D.J., et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008, 68:191-208.
64. French M.A. Antiretroviral therapy. Immune restoration disease in HIV-infected patients on HAART. AIDS Read 1999, 9:548-549. 554-555, 559-562.
65. Antonelli L.R., et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 2010, 116:3818-3827.
66. Bourgarit A., et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. Aids 2006, 20:F1-F7.
67. Gilquin J., et al. Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy. Lancet 1998, 352:1907-1908.
68. Miralles P., et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. Aids 2001, 15:1900-1902.
69. Hsieh S.M., et al. Association between cytomegalovirus-specific reactivity of T cell subsets and development of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. J. Infect. Dis. 2001, 184:1386-1391.
70. Bourgarit A., et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells. J. Immunol. 2009, 183:3915-3923.
71. Price P., et al. Killer immunoglobulin-like receptor genotype may distinguish immunodeficient HIV-infected patients resistant to immune restoration diseases associated with herpes virus infections. J. Acquir. Immune Defic. Syndr. 2007, 45:359-361.
72. Seddiki N., et al. Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. Eur. J. Immunol. 2009, 39:391-403.
73. Porter B.O., et al. d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS. Clin. Immunol. 2010, 136:42-50.
74. Lawn S.D., et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. Aids 2009, 23:1717-1725.
75. Price P., et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. Aids 2002, 16:2043-2047.
76. Schacker T.W., et al. Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV. J Acquir Immune Defic Syndr. 2010, 54:59-62.
77. Wood E., et al. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J Infect Dis 2003, 188:1421-1425.
78. Egger M., et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.